Clinical Trial Update: TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

Phase 2 trial update for TAK-659 in relapsed or refractory diffuse large B-cell lymphoma has been terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• TAK-659 (TAK-659)

Snippet

Sponsor: Calithera Biosciences, Inc | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2020-09-16